Skip to main content
. 2003 Sep-Dec;9(9-12):193–199. doi: 10.2119/2004-00002.johansson

Figure 3.

Figure 3

Plasma kinetics for human recombinant porphobilinogen deaminase (rhPBGD) administered intravenously or subcutaneously. For the intravenous administration, 50 μg rhPBGD was injected into the tail vein, and for the subcutaneous administration, 300 μg rhPBGD was injected in the neck. The PBGD activity was expressed as nkat/L. Each data point represents 1 animal.